Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.

scientific article

Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2012PLoSO...750005R
P356DOI10.1371/JOURNAL.PONE.0050005
P932PMC publication ID3503708
P698PubMed publication ID23185517
P5875ResearchGate publication ID233775692

P50authorS. Vincent RajkumarQ61123608
Shaji K KumarQ85960198
P2093author name stringVijay Ramakrishnan
Utkarsh Painuly
Jessica Haug
Teresa Kimlinger
Linda Wellik
Timothy Halling
P2860cites workTwo distinct human myeloma cell lines originating from one patient with myeloma.Q52833946
Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma.Q54116960
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.Q54422243
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.Q54702844
Treatment of multiple myelomaQ83975326
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factorQ22009126
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinaseQ24300915
Mechanism of activation of protein kinase B by insulin and IGF-1Q24309528
Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylationQ24312168
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Q24321567
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signalingQ24536092
mTOR: from growth signal integration to cancer, diabetes and ageingQ24633662
Phosphorylation and regulation of Raf by Akt (protein kinase B)Q28138863
Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiencyQ28249019
Interleukin-3-induced phosphorylation of BAD through the protein kinase AktQ28255373
The LKB1 tumor suppressor negatively regulates mTOR signalingQ28272728
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteinsQ28507365
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsQ29547463
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stressQ29614493
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerQ29618030
Phosphoinositide kinasesQ29618047
TOR signalingQ30312086
Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.Q30452681
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myelomaQ33383550
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyQ33942495
Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondriaQ33959022
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsQ34134557
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyQ34306865
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.Q34374071
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activityQ34511038
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.Q35256272
Defining the role of TORC1/2 in multiple myelomaQ35631315
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneQ36663554
Perifosine: update on a novel Akt inhibitor.Q37393008
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myelomaQ39465626
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survivalQ39621100
ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).Q39632887
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.Q39718152
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsQ39771144
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.Q39827794
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.Q39830937
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsQ40087316
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsQ40328451
Analysis of PTEN deletions and mutations in multiple myelomaQ40383211
Downstream effectors of oncogenic ras in multiple myeloma cellsQ40679257
Development and characterization of a melphalan-resistant human multiple myeloma cell lineQ41697179
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytesQ42809294
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myelomaQ43761443
Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.Q43901688
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsQ44098361
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trialQ44442859
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.Q46615053
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)e50005
P577publication date2012-11-21
P1433published inPLOS OneQ564954
P1476titleAnti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway
P478volume7

Reverse relations

cites work (P2860)
Q38218256AKT as a therapeutic target in multiple myeloma
Q35236076Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.
Q90394240Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma
Q57818334Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
Q38718211Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.
Q88287160Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation
Q89964186Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines
Q35667885Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines
Q38112176Emerging pathways as individualized therapeutic target of multiple myeloma.
Q36737884Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy
Q37583378Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization
Q33875590Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
Q37697253Kinase inhibitors as potential agents in the treatment of multiple myeloma
Q35594600Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines
Q35615252MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma
Q38950582Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Q38690290Novel investigational drugs active as single agents in multiple myeloma.
Q28081590Novel therapeutic strategies for multiple myeloma
Q53055574PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
Q48263465PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Q27700745Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
Q34158470Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways
Q34075096Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition
Q38753307Signaling Pathways and Emerging Therapies in Multiple Myeloma
Q37636618Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
Q47618731The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs
Q47094892Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
Q52910208[Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways].

Search more.